Lead Product(s) : OSE-230
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : AbbVie Inc
Deal Size : $713.0 million
Deal Type : Licensing Agreement
OSE Global License for Novel Antibody for Chronic Inflammation Becomes Effective
Details : Under the licensing agreement, AbbVie to develop OSE-230, a monoclonal antibody designed to resolve chronic and severe inflammation, currently in the pre-clinical development stage.
Product Name : OSE-230
Product Type : Antibody
Upfront Cash : $48.0 million
April 16, 2024
Lead Product(s) : OSE-230
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : AbbVie Inc
Deal Size : $713.0 million
Deal Type : Licensing Agreement
Lead Product(s) : OSE-230
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : AbbVie Inc
Deal Size : $713.0 million
Deal Type : Partnership
AbbVie and OSE Immunotherapeutics Partner for Chronic Inflammation Therapy
Details : The partnership aims to focus on the development of OSE-230, which is an agonist antibody against ChemR23. It is being evaluated in the preclinical trial studies for chronic and severe inflammation.
Product Name : OSE-230
Product Type : Antibody
Upfront Cash : $48.0 million
February 28, 2024
Lead Product(s) : OSE-230
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : AbbVie Inc
Deal Size : $713.0 million
Deal Type : Partnership
Lead Product(s) : OSE-230
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The poster presentation highlights efficacy results for OSE-230 in chronic inflammatory preclinical models and ex vivo human models.inflammatory preclinical models and ex vivo human models.
Product Name : OSE-230
Product Type : Antibody
Upfront Cash : Inapplicable
October 30, 2020
Lead Product(s) : OSE-230
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable